Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

Why counsel should watch Novartis SCOTUS appeal

Rani Mehta
September 22, 2022
Share
NovartisCOVER.jpg
Credit: Taljat / Adobe Stock

Novartis’s planned SCOTUS appeal may be a long shot, but the case raises interesting Section 112 and procedural questions, say counsel

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Tags

AnalysisNewsUnited StatesPatentsLife sciences
rani-mehta-300px.png
Rani Mehta
US Reporter Managing IP
Contact
Rani reports on all aspects of IP in the US and the Americas, particularly trademarks and copyright. Based in New York, she covers in-house and private practice lawyers' concerns and insights into the market.
more from across site and ros bottom lb

More from across our site

EPO
This week on MIP: France v EPO spat, Med-El loss
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Rory O’Neill, May 26, 2023
INTA 2023.jpeg
AI, thriftiness, and law firm culture: takeaways from INTA 2023
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
Sukanya Sarkar, May 26, 2023
dollar money and judges gavel on table
Counsel: Federal Circuit right to clarify attorney fee challenge
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
Rani Mehta, May 25, 2023
economic crash-comp.jpg
Three principles for managing trademarks during a downturn
With business confidence in a shaky state, Rachel Tan and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
Lisa Yong, May 25, 2023
Entrance to the Royal Court of Justice
Med-El loses UK appeal in Advanced Bionics fight
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Rory O’Neill, May 24, 2023
Credit: Dennis / Adobe Stock
Three takeaways from Intel’s PTAB win
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
Rani Mehta, May 24, 2023
Berlin / Germany - September 22, 2019: Sanofi Germany - Berlin b
Amgen v Sanofi won’t upend in-house IP strategies: counsel
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel
Rani Mehta, May 23, 2023
A&O take-comp.jpg
Weekly take: A&O and Shearman’s billion-dollar baby could be trendsetter
Previous attempts at major transatlantic tie-ups have failed, so lawyers will keep their eyes firmly on Allen & Overy’s grand plans
Max Walters, May 23, 2023
Etienne_Sanz_de_Acedo_03-comp.jpg
INTA chief: transparency will guide my EUIPO campaign
INTA CEO Etienne Sanz de Acedo shares his plans if he were to win the EUIPO leadership race and says his application does not affect his INTA role
Sukanya Sarkar, May 23, 2023
French gov 2k-comp.jpg
French govt complained to EPO over EUIPO election conduct
The French finance minister told António Campinos the timing of an EPO event in Lisbon could be seen as interference in the EUIPO leadership race
Rory O’Neill, May 22, 2023